Biotech · Private company · Newton, MA, US
Abcuro, Inc.
SEC CIK 0001692147
Track this companyFree. Adds Abcuro, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ABC008Phase 3 · Inclusion Body MyositisClinicalTrials.gov · fetched Nov 12, 2026
- Ulviprubart (ABC008)Phase 3 · Inclusion Body Myositis (IBM)ClinicalTrials.gov · fetched Nov 12, 2026
- ABC008Phase 2 · T-cell Large Granular Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 21, 2024ClinicalTrials.gov NCT06450886 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body MyositisPHASE2_PHASE3 · COMPLETED · started Feb 28, 2023ClinicalTrials.gov NCT05721573 · fetched Nov 12, 2026
- ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)PHASE1_PHASE2 · COMPLETED · started Sep 28, 2022ClinicalTrials.gov NCT05532722 · fetched Nov 12, 2026